Sports
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions
Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering Robust and sustainable treatment effects support at least bi-annual dosing regimen
By: prnewswire_apac
- Nov 18 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS